ment. 2, 3 In CHiP, most children in the control group were spontaneously "normoglycemic" according to the authors' definition (blood glucose level, 122 mg per deciliter [6.8 mmol per liter] on day 1 and 114 mg per deciliter [6.3 mmol per liter] thereafter). Hence, the population at risk was diluted by a population not at risk, rendering statistical power insufficient. Since tight glucose control prevents later complications, 4 only the more critically ill patients who had more severe hyperglycemia and longer stays in the hospital -just a fraction of the patients in this studymay possibly benefit. The length of hospital stay in this study was 5 days shorter with tight glycemic control than with conventional treatment. This effect occurred late and was confirmed by the analysis of costs in the 12 months after randomization, so that more weight was given to patients with longer stays in the hospital. 5 Future trials of tight glucose control in children in ICUs should therefore select only patients "at risk" (with hyperglycemia) or increase the sample size. Follow-up should not be limited to 30 days. To the Editor: After more than a decade of tight glycemic control in critically ill patients, whether this should be considered a best practice remains a controversial subject, mainly in pediatric patients. 1,2 The study by Macrae et al. appears to be relevant to this topic, since, in addition to assessment of the financial impact of this treatment, it evaluated patients after cardiac surgery and with other clinical conditions. Other studies have suggested that hyperglycemia can result in worse outcomes. 1,2 However, a recent study has emphasized stress hyperglycemia as an evolutionarily preserved adaptive response that increases the survival rate. 3 The incidence of hypoglycemia varies in studies comparing tight glucose control and conventional treatment, mainly because of different populations and discrepant glycemic ranges. The incidence is higher in studies of tight glucose control 1,2 such as the study by Macrae et al. Despite the occurrence of seizures in patients in this trial, there was no long-term follow-up to evaluate the possible sequelae.
Advanced forms of technology such as computerized glucose control 4 have paved the way for future research and better clinical practices to distinguish groups that can really benefit from tight glucose control. Which path should be followed? New pediatric trials of tight glucose control should be considered, with the use of physiological mechanisms to reduce the occurrence of adverse effects. 
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The Authors Reply: Van den Berghe and Mesotten describe the variability that we noted in our article in the four pediatric randomized, controlled trials of glucose control that used insulin; these trials involved a total of 3438 patients. 1,2 However, the most marked difference in each study is the use of insulin, not the glucose concentrations. We therefore question the usefulness of further randomized, controlled trials focused solely on glucose control.
Van den Berghe and Mesotten suggest that a future randomized, controlled trial should focus on children with marked hyperglycemia. Our trial was not limited to such a population. Rather, it answered the practical question of whether a glucose level of 72 to 126 mg per deciliter should be targeted in children in the pediatric ICU who required placement of an arterial catheter, mechanical ventilation, and vasoactive drug therapy. We concluded that in those circumstances, tight glycemic control had no effect on major clinical outcomes 30 days after randomization. A subgroup analysis based on severity-of-illness scores to determine the risk of death did not suggest that the effect was influenced by risk status, though that analysis had low power.
We fully agree that follow-up should not be limited to 30 days. We followed our patients for up to 1 year. The main benefits of glucose control were for patients in the non-cardiac-surgery subgroup, in whom hospital stay and costs up to 1 year were reduced.
Other than for a small number of children who had traumatic brain injury, our follow-up of children who did not remain in or who were not readmitted to the ICU on day 30 was only to determine how many patients had died and to assess for parent-reported use of health services, which could be seen as indicators of morbidity. We strongly agree that a range of clinically relevant longer-term end points should be part of any future randomized, controlled trials involving children in the pediatric ICU, and we agree Copyright © 2014 Massachusetts Medical Society. All rights reserved.
